BioMimetic (BMTI) Receives FDA Panel Backing For Augment Bone Graft
Tweet
Share
E-mailGet Alerts BMTI Hot Sheet
Join SI Premium – FREE
BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced late Thursday that the FDA Orthopedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee voted 12-6 in support of the safety of Augment Bone Graft for use as an alternative to autograft in hindfoot and ankle fusion procedures. The panel also voted 10-8 in support of the efficacy of Augment for use as an alternative to autograft in hindfoot and ankle fusions. Additionally, the panel voted 10-8 that Augment demonstrates a favorable benefit to risk profile for the same indication.
Share of BioMimetic should resume trading shortly after being halted all day yesterday.
Share of BioMimetic should resume trading shortly after being halted all day yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citigroup set to join top banks in Anthropic IPO - Bloomberg
- D.E. Shaw owns $1B+ stake in Sysco - Reuters
- Invesco cuts fees 20% amid redemption backlog in real estate fund - Bloomberg
Create E-mail Alert Related Categories
FDA, Hot FDA News, Trader Talk, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
